FDA Clears Iovance's Next-Gen TIL Therapy IOV-5001 for Solid Tumor Trials
IOVA has more than doubled off its 52-week low of $1.66.
Summary
Iovance Biotherapeutics received FDA clearance for its Investigational New Drug (IND) application for IOV-5001, a next-generation IL-12 tethered TIL therapy. This allows the company to initiate Phase 1/2 trials in the second half of 2026 for various solid tumors, including advanced colorectal and breast cancers, representing a large patient population. The therapy is designed to enhance efficacy and safety by localizing IL-12 expression within the tumor. This development significantly expands Iovance's clinical pipeline beyond its existing FDA-approved Amtagvi therapy and could open new treatment frontiers for difficult-to-treat cancers.
At the time of this announcement, IOVA was trading at $4.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $1.66 to $5.63. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.